Exploration of the host haemostatic system by group A streptococcus: Implications in searching for novel antimicrobial therapies

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 1 S, 2011, Pages 189-194

  Sun, H ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

Antimicrobial therapy; Group A streptococcus; Haemostatic factor

Indexed keywords

ACTIVATED PROTEIN C; ALBUMIN; ALPHA ENOLASE; ANTIINFECTIVE AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BRADYKININ; BRADYKININ ANTAGONIST; CD11B ANTIGEN; FIBRINOGEN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEPARIN BINDING PROTEIN; HUMAN NEUTROPHIL PEPTIDE; IMMUNOGLOBULIN; KININOGEN; M PROTEIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; STAPHYLOKINASE; STREPTOKINASE; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VIRULENCE FACTOR;

ANTIMICROBIAL THERAPY; BACTERIAL STRAIN; BACTERIUM ADHERENCE; BINDING SITE; BORRLELIA BURGDORFERI; DISEASE SEVERITY; FIBRINOLYSIS; GROUP A STREPTOCOCCAL INFECTION; HEMOSTASIS; HOST RESISTANCE; HOST SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; IMPETIGO; LYME DISEASE; NECROTIZING FASCIITIS; NONHUMAN; PERITONITIS; PHAGOCYTOSIS; PLASMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SCARLET FEVER; SEPSIS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PYOGENES; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE; THROMBOSIS; TONSILLITIS; TOXIC SHOCK SYNDROME; TRANSGENE; URINARY TRACT INFECTION; YERSINIA PESTIS;

ANIMALS; HEMOSTASIS; HOST-PATHOGEN INTERACTIONS; STREPTOCOCCUS PYOGENES;

EID: 79960619462     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04316.x     Document Type: Review

References (72)

1. Alanis AJ. Resistance to antibiotics: are we in the post-antibiotic era? Arch Med Res 2005; 36: 697-705.
2. Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 2003; 111: 1265-73.
3. Norrby SR, Nord CE, Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis 2005; 5: 115-9.
4. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
5. Theuretzbacher U. Future antibiotics scenarios: is the tide starting to turn? Int J Antimicrob Agents 2009; 34: 15-20.
6. Levi M. Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient. J Crit Care 2001; 16: 167-77.
7. Levi M, Keller TT, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res 2003; 60: 26-39.
8. Sun H. The interaction between pathogens and the host coagulation system. Physiology (Bethesda) 2006; 21: 281-8.
9. Bergmann S, Hammerschmidt S. Fibrinolysis and host response in bacterial infections. Thromb Haemost 2007; 98: 512-20.
10. Degen JL, Bugge TH, Goguen JD. Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost 2007; 5: 24-31.
11. Frick IM, Bjorck L, Herwald H. The dual role of the contact system in bacterial infectious disease. Thromb Haemost 2007; 98: 497-502.
12. Coleman JL, Gebbia JA, Piesman J, Degen JL, Bugge TH, Benach JL. Plasminogen is required for efficient dissemination of B. burgdorferi in ticks and for enhancement of spirochetemia in mice. Cell 1997; 89: 1111-9.
13. Hu LT, Perides G, Noring R, Klempner MS. Binding of human plasminogen to Borrelia burgdorferi. Infect Immun 1995; 63: 3491-6.
14. Sodeinde OA, Subrahmanyam YV, Stark K, Quan T, Bao Y, Goguen JD. A surface protease and the invasive character of plague. Science 1992; 258: 1004-7.
15. Lathem WW, Price PA, Miller VL, Goldman WE. A plasminogen-activating protease specifically controls the development of primary pneumonic plague. Science 2007; 315: 509-13.
16. Sebbane F, Jarrett CO, Gardner D, Long D, Hinnebusch BJ. Role of the Yersinia pestis plasminogen activator in the incidence of distinct septicemic and bubonic forms of flea-borne plague. Proc Natl Acad Sci USA 2006; 103: 5526-30.
17. Bokarewa MI, Jin T, Tarkowski A. Staphylococcus aureus: Staphylokinase. Int J Biochem Cell Biol 2006; 38: 504-9.
18. Jin T, Bokarewa M, Foster T, Mitchell J, Higgins J, Tarkowski A. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J Immunol 2004; 172: 1169-76.
19. Jin T, Bokarewa M, Zhu Y, Tarkowski A. Staphylokinase reduces plasmin formation by endogenous plasminogen activators. Eur J Haematol 2008; 81: 8-17.
20. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334: 240-5.
21. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5: 685-94.
22. Tillett WS, Garner RL. The fibrinolytic activity of hemolytic Streptococci. J Exp Med 1933; 58: 485-502.
23. Christensen LR, Macleod CM. A proteolytic enzyme of serum: characterization, activation, and reaction with inhibitors. J Gen Physiol 1945; 28: 559-83.
24. Esmon CT, Mather T. Switching serine protease specificity. Nat Struct Biol 1998; 5: 933-7.
25. Wang H, Lottenberg R, Boyle MD. A role for fibrinogen in the streptokinase-dependent acquisition of plasmin(ogen) by group A streptococci. J Infect Dis 1995; 171: 85-92.
26. Wang H, Lottenberg R, Boyle MD. Analysis of the interaction of group A streptococci with fibrinogen, streptokinase and plasminogen. Microb Pathog 1995; 18: 153-66.
27. Marcum JA, Kline DL. Species specificity of streptokinase. Comp Biochem Physiol B 1983; 75: 389-94.
28. Boyle MD, Lottenberg R. Plasminogen activation by invasive human pathogens. Thromb Haemost 1997; 77: 1-10.
29. Khil J, Im M, Heath A, Ringdahl U, Mundada L, Engleberg NC, Fay WP. Plasminogen enhances virulence of group A streptococci by streptokinase-dependent and streptokinase-independent mechanisms. J Infect Dis 2003; 188: 497-505.
30. Sun H, Ringdahl U, Homeister JW, Fay WP, Engleberg NC, Yang AY, Rozek LS, Wang X, Sjobring U, Ginsburg D. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 2004; 305: 1283-6.
31. Walker MJ, McArthur JD, McKay F, Ranson M. Is plasminogen deployed as a Streptococcus pyogenes virulence factor? Trends Microbiol 2005; 13: 308-13.
32. Wistedt AC, Ringdahl U, Muller-Esterl W, Sjobring U. Identification of a plasminogen-binding motif in PAM, a bacterial surface protein. Mol Microbiol 1995; 18: 569-78.
33. Ringdahl U, Svensson M, Wistedt AC, Renne T, Kellner R, Muller-Esterl W, Sjobring U. Molecular co-operation between protein PAM and streptokinase for plasmin acquisition by Streptococcus pyogenes. J Biol Chem 1998; 273: 6424-30.
34. Sanderson-Smith ML, Dowton M, Ranson M, Walker MJ. The plasminogen-binding group A streptococcal M protein-related protein Prp binds plasminogen via arginine and histidine residues. J Bacteriol 2007; 189: 1435-40.
35. Sanderson-Smith ML, Dinkla K, Cole JN, Cork AJ, Maamary PG, McArthur JD, Chhatwal GS, Walker MJ. M protein-mediated plasminogen binding is essential for the virulence of an invasive Streptococcus pyogenes isolate. FASEB J 2008; 22: 2715-22.
36. Winram SB, Lottenberg R. The plasmin-binding protein Plr of group A streptococci is identified as glyceraldehyde-3-phosphate dehydrogenase. Microbiology 1996; 142: 2311-20.
37. Pancholi V, Fischetti VA. alpha-enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci. J Biol Chem 1998; 273: 14503-15.
38. Boel G, Jin H, Pancholi V. Inhibition of cell surface export of group A streptococcal anchorless surface dehydrogenase affects bacterial adherence and antiphagocytic properties. Infect Immun 2005; 73: 6237-48.
39. Jin H, Song YP, Boel G, Kochar J, Pancholi V. Group A streptococcal surface GAPDH, SDH, recognizes uPAR/CD87 as its receptor on the human pharyngeal cell and mediates bacterial adherence to host cells. J Mol Biol 2005; 350: 27-41.
40. Terao Y, Yamaguchi M, Hamada S, Kawabata S. Multifunctional glyceraldehyde-3-phosphate dehydrogenase of Streptococcus pyogenes is essential for evasion from neutrophils. J Biol Chem 2006; 281: 14215-23.
41. Pancholi V. Multifunctional alpha-enolase: its role in diseases. Cell Mol Life Sci 2001; 58: 902-20.
42. Cork AJ, Jergic S, Hammerschmidt S, Kobe B, Pancholi V, Benesch JL, Robinson CV, Dixon NE, Aquilina JA, Walker MJ. Defining the structural basis of human plasminogen binding by streptococcal surface enolase. J Biol Chem 2009; 284: 17129-37.
43. Lahteenmaki K, Kuusela P, Korhonen TK. Bacterial plasminogen activators and receptors. FEMS Microbiol Rev 2001; 25: 531-52.
44. Sun H, Wang X, Degen JL, Ginsburg D. Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood 2009; 113: 1358-64.
45. Sun H, Yang TL, Yang A, Wang X, Ginsburg D. The murine platelet and plasma factor V pools are biosynthetically distinct and sufficient for minimal hemostasis. Blood 2003; 102: 2856-61.
46. Gould WR, Silveira JR, Tracy PB. Unique in vivo modifications of coagulation factor V produce a physically and functionally distinct platelet-derived cofactor: characterization of purified platelet-derived factor V/Va. J Biol Chem 2004; 279: 2383-93.
47. Castoldi E, Brugge JM, Nicolaes GA, Girelli D, Tans G, Rosing J. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood 2004; 103: 4173-9.
48. Flick MJ, Du X, Witte DP, Jirouskova M, Soloviev DA, Busuttil SJ, Plow EF, Degen JL. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest 2004; 113: 1596-606.
49. Oehmcke S, Shannon O, Morgelin M, Herwald H. Streptococcal M proteins and their role as virulence determinants. Clin Chim Acta 2010; 411: 1172-80.
50. Pahlman LI, Morgelin M, Eckert J, Johansson L, Russell W, Riesbeck K, Soehnlein O, Lindbom L, Norrby-Teglund A, Schumann RR, Bjorck L, Herwald H. Streptococcal M protein: a multipotent and powerful inducer of inflammation. J Immunol 2006; 177: 1221-8.
51. Shannon O, Hertzen E, Norrby-Teglund A, Morgelin M, Sjobring U, Bjorck L. Severe streptococcal infection is associated with M protein-induced platelet activation and thrombus formation. Mol Microbiol 2007; 65: 1147-57.
52. McKay FC, McArthur JD, Sanderson-Smith ML, Gardam S, Currie BJ, Sriprakash KS, Fagan PK, Towers RJ, Batzloff MR, Chhatwal GS, Ranson M, Walker MJ. Plasminogen binding by group A streptococcal isolates from a region of hyperendemicity for streptococcal skin infection and a high incidence of invasive infection. Infect Immun 2004; 72: 364-70.
53. Christner R, Li Z, Raeder R, Podbielski A, Boyle MD. Identification of key gene products required for acquisition of plasmin-like enzymatic activity by group A streptococci. J Infect Dis 1997; 175: 1115-20.
54. Hess JL, Boyle MD. Fibrinogen fragment D is necessary and sufficient to anchor a surface plasminogen-activating complex in Streptococcus pyogenes. Proteomics 2006; 6: 375-8.
55. D'Costa SS, Boyle MD. Interaction of a group A Streptococcus within human plasma results in assembly of a surface plasminogen activator that contributes to occupancy of surface plasmin-binding structures. Microb Pathog 1998; 24: 341-9.
56. Flick MJ, Du X, Degen JL. Fibrin(ogen)-alpha M beta 2 interactions regulate leukocyte function and innate immunity in vivo. Exp Biol Med (Maywood) 2004; 229: 1105-10.
57. Ringdahl U, Svensson HG, Kotarsky H, Gustafsson M, Weineisen M, Sjobring U. A role for the fibrinogen-binding regions of streptococcal M proteins in phagocytosis resistance. Mol Microbiol 2000; 37: 1318-26.
58. Rivera J, Vannakambadi G, Hook M, Speziale P. Fibrinogen-binding proteins of Gram-positive bacteria. Thromb Haemost 2007; 98: 503-11.
59. Herwald H, Cramer H, Morgelin M, Russell W, Sollenberg U, Norrby-Teglund A, Flodgaard H, Lindbom L, Bjorck L. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell 2004; 116: 367-79.
60. Smeesters PR, McMillan DJ, Sriprakash KS. The streptococcal M protein: a highly versatile molecule. Trends Microbiol 2010; 18: 275-82.
61. Oehmcke S, Herwald H. Contact system activation in severe infectious diseases. J Mol Med 2010; 88: 121-6.
62. Margarit I, Bonacci S, Pietrocola G, Rindi S, Ghezzo C, Bombaci M, Nardi-Dei V, Grifantini R, Speziale P, Grandi G. Capturing host-pathogen interactions by protein microarrays: identification of novel streptococcal proteins binding to human fibronectin, fibrinogen, and C4BP. FASEB J 2009; 23: 3100-12.
63. Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, Joyce DE, Weiler H, Dhainaut JF. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 2003; 102: 3085-92.
64. Yan SB, Nelson DR. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med 2004; 32: S239-46.
65. Weiler H, Kerlin B, Lytle MC. Factor V Leiden polymorphism modifies sepsis outcome: evidence from animal studies. Crit Care Med 2004; 32: S233-8.
66. Benfield TL, Dahl M, Nordestgaard BG, Tybjaerg-Hansen A. Influence of the factor v leiden mutation on infectious disease susceptibility and outcome: a population-based study. J Infect Dis 2005; 192: 1851-7.
67. Bruggemann LW, Schoenmakers SH, Groot AP, Reitsma PH, Spek CA. Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice. Crit Care Med 2006; 34: 2201-6.
68. Parker RI. Factor V Leiden and sepsis: proof positive or phenomenology? Crit Care Med 2006; 34: 2254-5.
69. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001; 86: 51-6.
70. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
71. Fein AM, Bernard GR, Criner GJ, Fletcher EC, Good JT Jr, Knaus WA, Levy H, Matuschak GM, Shanies HM, Taylor RW, Rodell TC. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA 1997; 277: 482-7.
72. Oehmcke S, Shannon O, von Kockritz-Blickwede M, Morgelin M, Linder A, Olin AI, Bjorck L, Herwald H. Treatment of invasive streptococcal infection with a peptide derived from human high-molecular weight kininogen. Blood 2009; 114: 444-51.